Drugs / SHR-A1904
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06350006 | May 2024 → Dec 2027 expected | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04928625 | Aug 2021 → Jun 2023 | pancreatic neoplasm | Shanghai Hengrui Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04877717 | Jul 2021 → Dec 2025 overdue | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05277168 | May 2022 → May 2026 overdue | cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07700719 | Jul 2026 → Nov 2027 expected | colorectal cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07520357 | Apr 2026 → Feb 2028 expected | neuroendocrine carcinoma | Beijing GoBroad Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07450976 | Mar 2026 → Dec 2030 expected | biliary tract cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07102901 | Sep 2025 → Dec 2027 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07110571 | Aug 2025 → Aug 2026 overdue | gastric cancer, gastroesophageal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06881017 | May 2025 → Aug 2029 expected | gastric cancer, gastroesophageal junction adenocarcinoma | China Medical University, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06547736 | Oct 2024 → Mar 2027 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06649292 | Nov 2024 → Sep 2027 expected | gastroesophageal adenocarcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-A1904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07110571 ↗ |
| Route | Intravenous | “iv，d1 ，q3w” NCT06881017 ↗ |